What question did this study set out to answer?

To explore the implications of omitting sentinel lymph node biopsy (SLNB) in patients with early-stage node-negative breast cancer undergoing mastectomy.

April 10, 2026Open Access

Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early-Stage Node-Negative HR+/HER2− Breast Cancer Undergoing Mastectomy

Key Points

To explore the implications of omitting sentinel lymph node biopsy (SLNB) in patients with early-stage node-negative breast cancer undergoing mastectomy.
Analyzed patients with cT1N0M0 HR+/HER2- disease and negative AUS
Compared early recurrence rates across different surgical types
Identified impact of nodal status on radiotherapy post-mastectomy
Early recurrence rates were found to be low irrespective of surgery type
Omission of SLNB may not significantly affect recurrence in this patient group
Need for further studies to solidify the rationale for SLNB omission

Abstract

Among patients with cT1N0M0 HR+/HER2- disease and negative AUS who underwent SLNB, early recurrence rates were low regardless of surgery type. Given that nodal status affects the use of RT after mastectomy, further research investigating the omission of SLNB in this cohort is warranted.

Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early-Stage Node-Negative HR+/HER2− Breast Cancer Undergoing Mastectomy

Key Points

Abstract

Cite This Study